论文部分内容阅读
目的评估卡维地洛治疗老年心力衰竭患者的耐受性。方法52例稳定性老年(>70岁)心力衰竭患者接受卡维地洛递增剂量治疗。治疗前后分别对血压、心率,心脏射血分数和纽约心脏病学协会(NYHA)分级进行检测,评判疗效和安全性。结果卡维地洛治疗后,患者收缩压从133.3mmHg降为120.8mmHg,舒张压从78.0mmHg降为70.4mmHg,治疗前后比较,差异均有统计学意义(P<0.01);心率从81.9次/min下降为70.7次/min(P<0.01),射血分数从39.8%上升为43.9%(P<0.05),NYHA分级下降;平均剂量为36.8mg/d,其中55.8%的患者可以耐受卡维地洛50mg/d,除2例退出,96.1%的老年患者心力衰竭可坚持卡维地洛治疗。结论老年心力衰竭患者基本可以耐受卡维地洛治疗。
Objective To evaluate the tolerability of carvedilol in elderly patients with heart failure. Methods Fifty-two elderly patients (> 70 years old) with stable heart failure underwent an escalating dose of carvedilol. Before and after treatment, blood pressure, heart rate, cardiac ejection fraction and New York Heart Association (NYHA) grading were tested to evaluate the efficacy and safety. Results After the treatment of carvedilol, the systolic blood pressure decreased from 133.3 mmHg to 120.8 mmHg and the diastolic pressure decreased from 78.0 mmHg to 70.4 mmHg. The difference was statistically significant before and after treatment (P <0.01) min (P <0.01), ejection fraction increased from 39.8% to 43.9% (P <0.05), NYHA grade decreased, mean dose was 36.8mg / d, of which 55.8% patients could tolerate card Vidoterat 50mg / d, with the exception of two patients quit, 96.1% of elderly patients with heart failure can adhere to the carvedilol treatment. Conclusion Elderly patients with heart failure can basically tolerate carvedilol.